DANIEL MUSHER to Pneumococcal Vaccines
This is a "connection" page, showing publications DANIEL MUSHER has written about Pneumococcal Vaccines.
Connection Strength
5.227
-
Should Committees That Write Guidelines and Recommendations Publish Dissenting Opinions? Mayo Clin Proc. 2016 05; 91(5):634-9.
Score: 0.467
-
Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother. 2016; 12(2):331-5.
Score: 0.459
-
The CAPITA study of protein-conjugate pneumococcal vaccine and its implications for use in adults in developed countries. Hum Vaccin Immunother. 2014; 10(5):1331-3.
Score: 0.409
-
How effective is vaccination in preventing pneumococcal disease? Infect Dis Clin North Am. 2013 Mar; 27(1):229-41.
Score: 0.377
-
Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin Infect Dis. 2012 Jul; 55(2):265-7.
Score: 0.355
-
Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin. 2011 Sep; 7(9):919-28.
Score: 0.340
-
The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis. 2011 Mar 01; 52(5):633-40.
Score: 0.328
-
Preventing myocardial infarction with vaccination: myths and realities. JAMA. 2010 May 05; 303(17):1751-2.
Score: 0.310
-
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010 Feb 15; 201(4):516-24.
Score: 0.305
-
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis. 2008 Oct 01; 198(7):1019-27.
Score: 0.278
-
Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis. 2006 Oct 15; 43(8):1004-8.
Score: 0.240
-
Pneumococcal vaccine--direct and indirect ("herd") effects. N Engl J Med. 2006 Apr 06; 354(14):1522-4.
Score: 0.234
-
Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis. 2005 Apr 01; 191(7):1063-7.
Score: 0.217
-
Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis. 2001 Jan 15; 32(2):307-10.
Score: 0.162
-
Genetic control of the immunologic response to pneumococcal capsular polysaccharides. Vaccine. 2000 Nov 08; 19(6):623-7.
Score: 0.161
-
The Ongoing Genetic Adaptation of Streptococcus pneumoniae. J Clin Microbiol. 2017 03; 55(3):681-685.
Score: 0.123
-
V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons. Clin Vaccine Immunol. 2011 Mar; 18(3):362-6.
Score: 0.081
-
Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. Cancer. 2008 Jul 15; 113(2):383-7.
Score: 0.068
-
Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2003 Aug 01; 37(3):438-47.
Score: 0.048
-
Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine. 2002 Nov 01; 20(31-32):3720-4.
Score: 0.046
-
Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J Investig Med. 1997 Feb; 45(2):57-68.
Score: 0.031
-
IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis. 1996 Jun; 173(6):1347-53.
Score: 0.030
-
Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia. Eur Respir J. 2016 09; 48(3):797-807.
Score: 0.029
-
Pneumococcal vaccination for patients with spinal cord injury. Arch Phys Med Rehabil. 1993 Dec; 74(12):1354-7.
Score: 0.025
-
Pneumococcal pneumonia including diagnosis and therapy of infection caused by penicillin-resistant strains. Infect Dis Clin North Am. 1991 Sep; 5(3):509-21.
Score: 0.021
-
The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century. Medicine (Baltimore). 2010 Sep; 89(5):331-336.
Score: 0.020
-
Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis. 1990 Apr; 161(4):728-35.
Score: 0.019
-
Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis. 1986 Aug; 154(2):245-56.
Score: 0.015
-
Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999 Aug; 29(2):281-8.
Score: 0.009
-
Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis. 1996 Jan; 173(1):83-90.
Score: 0.007
-
Pneumococcal vaccine after 15 years of use. Another view. Arch Intern Med. 1994 Nov 28; 154(22):2531-5.
Score: 0.007
-
Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis. 1992 Mar; 165(3):553-6.
Score: 0.005